Symbols / ADMA
ADMA Chart
About
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.74B |
| Enterprise Value | 3.75B | Income | 209.45M | Sales | 488.56M |
| Book/sh | 1.81 | Cash/sh | 0.26 | Dividend Yield | — |
| Payout | 0.00% | Employees | 677 | IPO | — |
| P/E | 18.23 | Forward P/E | 16.68 | PEG | — |
| P/S | 7.66 | P/B | 8.67 | P/C | — |
| EV/EBITDA | 21.45 | EV/Sales | 7.68 | Quick Ratio | 3.52 |
| Current Ratio | 7.13 | Debt/Eq | 19.28 | LT Debt/Eq | — |
| EPS (ttm) | 0.86 | EPS next Y | 0.94 | EPS Growth | -0.00% |
| Revenue Growth | 12.00% | Earnings | 2026-02-25 | ROA | 21.76% |
| ROE | 63.17% | ROIC | — | Gross Margin | 54.71% |
| Oper. Margin | 38.01% | Profit Margin | 42.87% | Shs Outstand | 238.00M |
| Shs Float | 233.24M | Short Float | 10.03% | Short Ratio | 8.33 |
| Short Interest | — | 52W High | 25.67 | 52W Low | 13.50 |
| Beta | 0.48 | Avg Volume | 2.38M | Volume | 4.81M |
| Target Price | $25.67 | Recom | None | Prev Close | $15.52 |
| Price | $15.68 | Change | 1.03% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$25.67
Mean price target
2. Current target
$15.68
Latest analyst target
3. DCF / Fair value
$0.22
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$15.68
Low
$17.00
High
$30.00
Mean
$25.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-08 | main | Raymond James | Strong Buy → Strong Buy | $32 |
| 2025-03-04 | reit | Cantor Fitzgerald | Overweight → Overweight | $25 |
| 2024-11-08 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2024-11-08 | main | Raymond James | Strong Buy → Strong Buy | $25 |
| 2024-10-14 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-09-20 | reit | Cantor Fitzgerald | Overweight → Overweight | $20 |
| 2024-08-12 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-08-09 | main | Cantor Fitzgerald | Overweight → Overweight | $20 |
| 2024-07-09 | main | Cantor Fitzgerald | Overweight → Overweight | $15 |
| 2024-06-20 | main | Mizuho | Buy → Buy | $14 |
| 2024-05-10 | main | Raymond James | Strong Buy → Strong Buy | $10 |
| 2024-05-10 | main | Cantor Fitzgerald | Overweight → Overweight | $10 |
| 2024-05-10 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-10 | main | Mizuho | Buy → Buy | $12 |
| 2024-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-03-01 | main | Mizuho | Buy → Buy | $10 |
| 2024-02-29 | main | Cantor Fitzgerald | Overweight → Overweight | $8 |
| 2024-02-29 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-01-22 | main | Mizuho | Buy → Buy | $9 |
| 2024-01-09 | main | HC Wainwright & Co. | Buy → Buy | $6 |
- ADMA Biologics Q4 Earnings Call Highlights - Yahoo Finance Wed, 25 Feb 2026 23
- Adma Biologics: Fourth Quarter Financial Overview - Bitget Wed, 25 Feb 2026 21
- Will ADMA’s (ADMA) Q4 2025 Earnings and Profit Focus Quiet Skeptics of Its Business Model? - simplywall.st Wed, 25 Feb 2026 10
- ADMA Biologics Inc earnings beat by $0.03, revenue fell short of estimates - Investing.com hu, 26 Feb 2026 00
- ADMA Biologics Announces CFO Transition and Leadership Change - TipRanks Wed, 25 Feb 2026 21
- ADMA Biologics Reports Strong Q4 2025 Earnings and Positive Outlook - Intellectia AI hu, 26 Feb 2026 00
- ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech With A 59.42% Potential Upside - DirectorsTalk Interviews Mon, 23 Feb 2026 19
- ADMA Biologics CFO Brad Tade retires; Terry Kohler promoted to CFO - TradingView Wed, 25 Feb 2026 21
- ADMA Biologics Q4 2025 Earnings Call Transcript - MarketBeat Wed, 25 Feb 2026 22
- (ADMA) ADMA Biologics Expects 2026 Revenue to Exceed $635M, vs. FactSet Est of $633.8M - marketscreener.com Wed, 25 Feb 2026 22
- ADMA Biologics (ADMA) Reports Strong 2025 Results and Positive O - GuruFocus hu, 26 Feb 2026 00
- Preview: ADMA Biologics's Earnings - Benzinga ue, 24 Feb 2026 16
- The Play On ADMA Biologics: A Discounted Stock With Good Prospects (NASDAQ:ADMA) - Seeking Alpha Fri, 12 Dec 2025 08
- ADMA Biologics earnings up next: Can momentum match lofty targets? - Investing.com Wed, 25 Feb 2026 16
- Is ADMA Biologics (ADMA) Pricing Reflecting Its Multi Year Share Price Surge? - simplywall.st hu, 19 Feb 2026 17
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 21000 | 337680 | — | Sale at price 16.08 per share. | GROSSMAN ADAM S | Chief Executive Officer | — | 2026-02-17 00:00:00 | D |
| 1 | 15000 | 81000 | — | Conversion of Exercise of derivative security at price 5.40 per share. | GROSSMAN ADAM S | Chief Executive Officer | — | 2026-02-17 00:00:00 | D |
| 2 | 10690 | — | — | Stock Award(Grant) at price 0.00 per share. | GROSSMAN JERROLD B | Director | — | 2026-02-09 00:00:00 | D |
| 3 | 282529 | — | — | Stock Award(Grant) at price 0.00 per share. | GROSSMAN ADAM S | Chief Executive Officer | — | 2026-02-09 00:00:00 | D |
| 4 | 10690 | — | — | Stock Award(Grant) at price 0.00 per share. | GUIHEEN LAWRENCE P | Director | — | 2026-02-09 00:00:00 | D |
| 5 | 10690 | — | — | Stock Award(Grant) at price 0.00 per share. | FINGER ALISON CECILY | Director | — | 2026-02-09 00:00:00 | D |
| 6 | 10690 | — | — | Stock Award(Grant) at price 0.00 per share. | KWON YOUNG T. PH.D. | Director | — | 2026-02-09 00:00:00 | D |
| 7 | 10690 | — | — | Stock Award(Grant) at price 0.00 per share. | ELMS STEVEN A | Director | — | 2026-02-09 00:00:00 | D |
| 8 | 10690 | — | — | Stock Award(Grant) at price 0.00 per share. | SALAS EDUARDO RENE | Director | — | 2026-02-09 00:00:00 | D |
| 9 | 91631 | — | — | Stock Award(Grant) at price 0.00 per share. | KESTENBERG-MESSINA KAITLIN M. | Officer | — | 2026-02-09 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -261.03K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | 148.93M | 31.29M | -32.84M | -53.09M |
| TotalUnusualItems | -1.24M | -26.17M | -6.67M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -1.24M | -26.17M | -6.67M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | 197.67M | -28.24M | -65.90M | -71.65M |
| ReconciledDepreciation | 8.04M | 8.33M | 7.11M | 5.50M |
| ReconciledCostOfRevenue | 199.24M | 161.66M | 112.42M | 74.99M |
| EBITDA | 147.69M | 5.12M | -39.51M | -53.09M |
| EBIT | 139.64M | -3.21M | -46.62M | -58.59M |
| NetInterestIncome | -11.83M | -23.41M | -19.23M | -13.02M |
| InterestExpense | 13.93M | 25.03M | 19.28M | 13.06M |
| InterestIncome | 2.10M | 1.62M | 45.00K | 35.00K |
| NormalizedIncome | 198.65M | -2.06M | -59.23M | -71.65M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 197.67M | -28.24M | -65.90M | -71.65M |
| TotalExpenses | 287.47M | 236.58M | 193.44M | 139.32M |
| TotalOperatingIncomeAsReported | 138.98M | 21.63M | -39.37M | -58.37M |
| DilutedAverageShares | 243.34M | 223.98M | 197.87M | 139.58M |
| BasicAverageShares | 233.08M | 223.98M | 197.87M | 139.58M |
| DilutedEPS | 0.81 | -0.13 | -0.33 | -0.51 |
| BasicEPS | 0.85 | -0.13 | -0.33 | -0.51 |
| DilutedNIAvailtoComStockholders | 197.67M | -28.24M | -65.90M | -71.65M |
| NetIncomeCommonStockholders | 197.67M | -28.24M | -65.90M | -71.65M |
| NetIncome | 197.67M | -28.24M | -65.90M | -71.65M |
| NetIncomeIncludingNoncontrollingInterests | 197.67M | -28.24M | -65.90M | -71.65M |
| NetIncomeContinuousOperations | 197.67M | -28.24M | -65.90M | -71.65M |
| TaxProvision | -71.96M | 0.00 | 0.00 | |
| PretaxIncome | 125.71M | -28.24M | -65.90M | -71.65M |
| OtherIncomeExpense | -1.44M | -26.46M | -7.30M | -252.00K |
| OtherNonOperatingIncomeExpenses | -193.00K | -287.00K | -635.00K | -252.00K |
| SpecialIncomeCharges | -1.24M | -26.17M | -6.67M | 0.00 |
| OtherSpecialCharges | 1.24M | 26.17M | 6.67M | |
| NetNonOperatingInterestIncomeExpense | -11.83M | -23.41M | -19.23M | -13.02M |
| InterestExpenseNonOperating | 13.93M | 25.03M | 19.28M | 13.06M |
| InterestIncomeNonOperating | 2.10M | 1.62M | 45.00K | 35.00K |
| OperatingIncome | 138.98M | 21.63M | -39.37M | -58.37M |
| OperatingExpense | 80.57M | 67.31M | 74.63M | 59.55M |
| OtherOperatingExpenses | 4.25M | 4.27M | 17.84M | 12.29M |
| DepreciationAmortizationDepletionIncomeStatement | 388.00K | 724.00K | 715.00K | 715.00K |
| DepreciationAndAmortizationInIncomeStatement | 388.00K | 724.00K | 715.00K | 715.00K |
| Amortization | 388.00K | 724.00K | 715.00K | 715.00K |
| AmortizationOfIntangiblesIncomeStatement | 388.00K | 724.00K | 715.00K | 715.00K |
| ResearchAndDevelopment | 1.81M | 3.30M | 3.61M | 3.65M |
| SellingGeneralAndAdministration | 74.12M | 59.02M | 52.46M | 42.90M |
| GrossProfit | 219.55M | 88.94M | 35.27M | 1.17M |
| CostOfRevenue | 206.90M | 169.27M | 118.81M | 79.77M |
| TotalRevenue | 426.45M | 258.21M | 154.08M | 80.94M |
| OperatingRevenue | 426.45M | 258.21M | 154.08M | 80.94M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 236.62M | 226.06M | 221.82M | 195.81M |
| ShareIssued | 236.62M | 226.06M | 221.82M | 195.81M |
| NetDebt | 79.24M | 56.31M | 43.78M | |
| TotalDebt | 82.12M | 141.42M | 154.44M | 102.92M |
| TangibleBookValue | 345.03M | 131.18M | 147.43M | 135.91M |
| InvestedCapital | 421.36M | 265.80M | 294.81M | 236.04M |
| WorkingCapital | 275.87M | 207.21M | 231.13M | 178.35M |
| NetTangibleAssets | 345.03M | 131.18M | 147.43M | 135.91M |
| CapitalLeaseObligations | 9.78M | 10.82M | 11.61M | 8.05M |
| CommonStockEquity | 349.02M | 135.21M | 151.97M | 141.17M |
| TotalCapitalization | 421.36M | 265.80M | 294.81M | 236.04M |
| TotalEquityGrossMinorityInterest | 349.02M | 135.21M | 151.97M | 141.17M |
| StockholdersEquity | 349.02M | 135.21M | 151.97M | 141.17M |
| RetainedEarnings | -308.58M | -506.26M | -478.02M | -412.11M |
| AdditionalPaidInCapital | 657.58M | 641.44M | 629.97M | 553.27M |
| CapitalStock | 24.00K | 23.00K | 22.00K | 19.58K |
| CommonStock | 24.00K | 23.00K | 22.00K | 19.58K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 139.66M | 193.98M | 196.49M | 135.08M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 84.12M | 144.17M | 157.22M | 104.70M |
| OtherNonCurrentLiabilities | 1.67M | 2.11M | 1.85M | 397.35K |
| NonCurrentDeferredLiabilities | 1.55M | 1.69M | 1.83M | 1.98M |
| NonCurrentDeferredRevenue | 1.55M | 1.69M | 1.83M | 1.98M |
| LongTermDebtAndCapitalLeaseObligation | 80.90M | 140.37M | 153.54M | 102.33M |
| LongTermCapitalLeaseObligation | 8.56M | 9.78M | 10.70M | 7.46M |
| LongTermDebt | 72.34M | 130.59M | 142.83M | 94.87M |
| CurrentLiabilities | 55.54M | 49.81M | 39.27M | 30.38M |
| OtherCurrentLiabilities | 1.85M | 2.37M | 1.80M | 1.01M |
| CurrentDeferredLiabilities | 143.00K | 182.00K | 143.00K | 142.83K |
| CurrentDeferredRevenue | 143.00K | 182.00K | 143.00K | 142.83K |
| CurrentDebtAndCapitalLeaseObligation | 1.22M | 1.04M | 905.00K | 591.08K |
| CurrentCapitalLeaseObligation | 1.22M | 1.04M | 905.00K | 591.08K |
| PayablesAndAccruedExpenses | 52.33M | 46.21M | 36.42M | 28.63M |
| CurrentAccruedExpenses | 28.63M | 30.55M | 23.19M | 16.20M |
| InterestPayable | 2.86M | 546.00K | ||
| Payables | 23.70M | 15.66M | 13.23M | 12.43M |
| TotalTaxPayable | 3.48M | 0.00 | ||
| IncomeTaxPayable | 3.48M | 0.00 | ||
| AccountsPayable | 20.22M | 15.66M | 13.23M | 12.43M |
| TotalAssets | 488.68M | 329.18M | 348.46M | 276.25M |
| TotalNonCurrentAssets | 157.27M | 72.17M | 78.06M | 67.52M |
| OtherNonCurrentAssets | 5.66M | 4.67M | 4.77M | 4.07M |
| NonCurrentPrepaidAssets | 4.07M | |||
| NonCurrentDeferredAssets | 84.28M | 0.00 | ||
| NonCurrentDeferredTaxesAssets | 84.28M | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 3.99M | 4.03M | 4.54M | 5.26M |
| OtherIntangibleAssets | 460.00K | 499.00K | 1.01M | 1.73M |
| Goodwill | 3.53M | 3.53M | 3.53M | 3.53M |
| NetPPE | 63.34M | 63.47M | 68.75M | 58.20M |
| AccumulatedDepreciation | -33.55M | -26.74M | -19.48M | -13.27M |
| GrossPPE | 96.89M | 90.21M | 88.22M | 71.47M |
| Leases | 21.07M | 20.81M | 17.93M | 11.13M |
| ConstructionInProgress | 8.15M | 2.27M | 6.73M | 5.50M |
| OtherProperties | 29.94M | 30.73M | 29.25M | 23.97M |
| MachineryFurnitureEquipment | 11.61M | 11.84M | 10.43M | 7.47M |
| BuildingsAndImprovements | 21.79M | 20.22M | 19.54M | 19.07M |
| LandAndImprovements | 4.34M | 4.34M | 4.34M | 4.34M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 331.41M | 257.01M | 270.40M | 208.73M |
| OtherCurrentAssets | 8.03M | 5.33M | 5.09M | 4.34M |
| PrepaidAssets | 4.34M | |||
| Inventory | 170.24M | 172.91M | 163.28M | 124.72M |
| FinishedGoods | 48.12M | 70.29M | 58.47M | 29.00M |
| WorkInProcess | 61.64M | 49.62M | 56.17M | 58.97M |
| RawMaterials | 60.47M | 53.00M | 48.64M | 36.76M |
| Receivables | 50.00M | 27.42M | 15.51M | 28.58M |
| AccountsReceivable | 50.00M | 27.42M | 15.51M | 28.58M |
| AllowanceForDoubtfulAccountsReceivable | -200.00K | -100.00K | -100.00K | -200.00K |
| GrossAccountsReceivable | 50.20M | 27.52M | 15.61M | 28.78M |
| CashCashEquivalentsAndShortTermInvestments | 103.15M | 51.35M | 86.52M | 51.09M |
| CashAndCashEquivalents | 103.15M | 51.35M | 86.52M | 51.09M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 110.10M | 3.82M | -73.42M | -125.88M |
| RepaymentOfDebt | -60.00M | -158.60M | -100.04M | -34.00K |
| IssuanceOfDebt | 0.00 | 135.00M | 151.75M | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 64.64M | 121.14M |
| CapitalExpenditure | -8.57M | -4.98M | -13.91M | -13.51M |
| InterestPaidSupplementalData | 10.67M | 18.05M | 13.88M | 11.16M |
| IncomeTaxPaidSupplementalData | 9.39M | 0.00 | 0.00 | |
| EndCashPosition | 103.15M | 51.35M | 86.52M | 51.09M |
| BeginningCashPosition | 51.35M | 86.52M | 51.09M | 55.92M |
| ChangesInCash | 51.80M | -35.17M | 35.43M | -4.83M |
| FinancingCashFlow | -58.30M | -38.99M | 108.85M | 121.05M |
| CashFlowFromContinuingFinancingActivities | -58.30M | -38.99M | 108.85M | 121.05M |
| NetOtherFinancingCharges | -5.80M | -16.49M | -7.68M | -62.00K |
| ProceedsFromStockOptionExercised | 7.49M | 1.10M | 175.00K | 0.00 |
| NetCommonStockIssuance | 0.00 | 0.00 | 64.64M | 121.14M |
| CommonStockIssuance | 0.00 | 0.00 | 64.64M | 121.14M |
| NetIssuancePaymentsOfDebt | -60.00M | -23.60M | 51.71M | -34.00K |
| NetLongTermDebtIssuance | -60.00M | -23.60M | 51.71M | -34.00K |
| LongTermDebtPayments | -60.00M | -158.60M | -100.04M | -34.00K |
| LongTermDebtIssuance | 0.00 | 135.00M | 151.75M | 0.00 |
| InvestingCashFlow | -8.57M | -4.98M | -13.91M | -13.51M |
| CashFlowFromContinuingInvestingActivities | -8.57M | -4.98M | -13.91M | -13.51M |
| NetIntangiblesPurchaseAndSale | -349.00K | -210.00K | 0.00 | 0.00 |
| PurchaseOfIntangibles | -349.00K | -210.00K | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -8.23M | -4.77M | -13.91M | -13.51M |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -8.23M | -4.77M | -13.91M | -13.51M |
| OperatingCashFlow | 118.67M | 8.80M | -59.51M | -112.37M |
| CashFlowFromContinuingOperatingActivities | 118.67M | 8.80M | -59.51M | -112.37M |
| ChangeInWorkingCapital | -18.54M | -10.12M | -18.29M | -51.68M |
| ChangeInOtherCurrentLiabilities | -1.14M | -791.00K | -502.00K | 219.00K |
| ChangeInPayablesAndAccruedExpense | 5.19M | 11.37M | 8.33M | 9.70M |
| ChangeInAccruedExpense | 1.04M | 7.53M | 7.53M | 8.34M |
| ChangeInPayable | 4.15M | 3.84M | 800.00K | 1.36M |
| ChangeInAccountPayable | 4.15M | 3.84M | 800.00K | 1.36M |
| ChangeInPrepaidAssets | -2.68M | 841.00K | -634.00K | -3.07M |
| ChangeInInventory | 2.67M | -9.63M | -38.56M | -43.19M |
| ChangeInReceivables | -22.58M | -11.92M | 13.07M | -15.34M |
| ChangesInAccountReceivables | -22.58M | -11.92M | 13.07M | -15.34M |
| OtherNonCashItems | 808.00K | 6.29M | 5.26M | 1.75M |
| StockBasedCompensation | 13.62M | 6.19M | 5.21M | 3.49M |
| DeferredTax | -84.28M | 0.00 | 0.00 | |
| DeferredIncomeTax | -84.28M | 0.00 | 0.00 | |
| DepreciationAmortizationDepletion | 8.04M | 8.33M | 7.11M | 5.50M |
| DepreciationAndAmortization | 8.04M | 8.33M | 7.11M | 5.50M |
| OperatingGainsLosses | 1.35M | 26.36M | 7.10M | 221.00K |
| GainLossOnSaleOfPPE | 106.00K | 182.00K | 427.00K | 221.00K |
| NetIncomeFromContinuingOperations | 197.67M | -28.24M | -65.90M | -71.65M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ADMA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|